Remdesivir is an adenosine nucleotide analog prodrug with broad-spectrum antiviral activity demonstrated both in vitro and in vivo in animal models. It has shown efficacy against Ebola virus , Marburg virus , SARS-CoV , and MERS-CoV .
The drug is manufactured by Gilead Sciences .
Mechanism of Action
Remdesivir is a prodrug of GS-441524 , which must undergo intracellular metabolism to its active triphosphate form. As an adenosine analog , it mimics natural adenosine but is structurally distinct.
Once inside infected cells:
- The active metabolite GS-443902 (triphosphate form) competes with adenosine triphosphate (ATP) for incorporation into viral RNA by viral RNA-dependent RNA polymerase (RdRp) .
- This results in premature termination of RNA transcription —specifically, the polymerase halts RNA synthesis at i + 3 nucleotides after remdesivir is incorporated.
- Importantly, the drug evades viral proofreading by 3′–5′ exoribonuclease (ExoN) , leading to defective viral genomes and inhibition of viral replication.
Antiviral Spectrum
- Previously tested against : Ebola, Marburg virus, SARS-CoV, and MERS-CoV.
- Current relevance : Demonstrated significant in vitro inhibition of SARS-CoV-2 , the virus responsible for COVID-19.
Uses and Indications
- Ebola virus disease : Trialed but did not show adequate efficacy.
- Marburg virus : Investigated for therapeutic use.
- COVID-19 : Authorized under Emergency Use Authorization (EUA) for hospitalized patients with moderate to severe disease. Multiple Phase III clinical trials are ongoing to determine its optimal use.
Administration
- Route : Intravenous (IV) infusion.
- Dosing durations :
- 5-day regimen for most patients.
- 10-day regimen considered for patients requiring invasive mechanical ventilation or ECMO.
Pharmacokinetics
- Metabolism : Hepatic metabolism via esterase hydrolysis followed by conversion to GS-441524.
- Enzymatic involvement : Partially metabolized by CYP2C8, CYP2D6, and CYP3A4 .
- Excretion : Primarily renal.
Adverse Effects
- Common :
- Nausea
- Vomiting
- Transaminitis (elevation of liver transaminases)
- Less common but significant :
- Respiratory failure
- Hypokalemia
- Hypoalbuminemia
- Anemia
- Thrombocytopenia
- Jaundice
Viral Resistance
The 3′–5′ exoribonuclease (ExoN) enzyme in coronaviruses can recognize and remove erroneous nucleotides , potentially reducing remdesivir's efficacy . Mutations in the ExoN gene may increase resistance to the drug by enhancing proofreading or reducing incorporation of the analog.
Drug Interactions
- CYP450 inducers such as rifampicin , carbamazepine , phenytoin , and phenobarbital can lower plasma concentrations of remdesivir, possibly reducing its therapeutic effect.
- Use with caution when co-administered with these agents.
Molecular Background and Replication Cycle of SARS-CoV-2
- The S (Spike) protein of SARS-CoV-2 binds to ACE2 receptors on host cells.
- After entry, the virus releases RNA, forms an RNA replicase-transcriptase complex , and uses host ribosomes to translate viral proteins.
- The RNA-dependent RNA polymerase (RdRp) synthesizes new viral RNA strands, which combine with structural proteins to form new virions that are released by exocytosis .
- Remdesivir interrupts this cycle by interfering with the RdRp , inhibiting viral RNA synthesis.
Current Research and Status
- Emergency Use Authorization granted for treatment of hospitalized patients with COVID-19.
- Ongoing clinical trials aim to determine:
- Optimal dosing duration
- Efficacy across different severity levels
- Long-term outcomes
